After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small cell lung cancer (SCLC). According to Merck, known as MSD outside North America, the company decided to voluntary withdraw this indication after consulting with the U.S. Food and Drug Administration (FDA). The process will be complete in the coming weeks. Healthcare professionals are being informed of the…
You must be logged in to read/download the full post.
The post Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US appeared first on BioNewsFeeds.